Figure 4
Survival curves of the patients with stage II / III NSCLC on the basis of GIRK1 amplification. A significant difference was not seen between the 2 groups.
Figure 4 | BMC Cancer
Survival curves of the patients with stage II / III NSCLC on the basis of GIRK1 amplification. A significant difference was not seen between the 2 groups.